-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen’s…
-
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
•
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from the National Medical Products Administration (NMPA). The small-molecule MET inhibitor is now approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET14 exon hopping. Development and Clinical FindingsGlumetinib, co-developed…
-
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
•
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The funding was led by Green Pine Capital Partners, with contributions from ZDVC and existing investor HM Capital, among others. This investment will…
-
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in first-line high-risk large B-cell lymphoma. The first patient has already completed reinfusion therapy, marking a significant step in the study’s progress. Previous Study ResultsThe pivotal RELIANCE study previously demonstrated that…
-
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in a Series A financing round led by Sinovac, with contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The proceeds will be used to develop and construct a comprehensive heart failure…
-
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
•
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand their one-stop oral soluble film research and development (R&D) and production services. The collaboration aims to enhance their capabilities in this innovative drug delivery system, with no financial details disclosed. Advantages of Oral Soluble FilmsOral…
-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). The agreement grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite platform and…
-
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
•
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical Co., Ltd, focusing on the over-active bladder (OAB) therapy Gemtesa (vibegron). This strategic agreement grants Sumitomo development, manufacturing, and commercialization rights to vibegron in key Asian markets, including Taiwan and Hong Kong in China, Singapore,…
-
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The…
-
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
•
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607). The partnership aims to accelerate the development of Akeso’s cadonilimab (AK104) in combination with Shanghai Pharmaceuticals’ SPH4336 for the treatment of well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS). About…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
-
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical Products Administration (NMPA) to conduct an open-label Phase I dosage escalation study. The study will assess the safety, tolerability, and preliminary anti-tumor activity of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (BsAb)…
-
Heranova Closes $10M Seed Round for Women’s Health Solutions
•
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of a seed financing round at USD 10 million. The round was co-led by Pivotal Bioventure Partners and Sinovation Ventures, with the proceeds earmarked for commercialization efforts in the Asia-Pacific region. This includes the market launch…
-
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
•
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed at the Hainan branch of Shanghai’s Ruijin Hospital. This marks a significant milestone in the availability of the oral spleen tyrosine kinase (SYK) inhibitor for the treatment of immunization thrombocytopenia (ITP) in China. Background and…
-
BrightGene’s Generic Halaven Approved for Marketing in China
•
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Japan-based Eisai’s (TYO: 4523) cancer therapy Halaven (eribulin). The approval signifies that BrightGene’s product, trade-named BoLiNing, has passed the generic quality consistency evaluation (GQCE). BoLiNing is…
-
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
•
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed. About AbcamAbcam is…
-
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
•
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights…
-
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
•
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by SND Financial Holdings, with participation from JM Capital, CDH Investments, Hui Ding Capital, 10Fund, and Boya Clivia Venture Capital.…
-
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
•
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity (mobocertinib) in China. The Japanese pharmaceutical giant will partner with China-based health platform MediTrust Health to launch innovative payment solutions for the drug in China, making this advanced therapy more accessible to patients. Clinical Need…
